The easy answer is budget.
Or headcount.
Or the wrong agency.
The real answer is usually structural.
MedTech marketing operates under a set of constraints that generic marketing playbooks weren’t built to handle. And then companies treat those constraints as background noise rather than core strategic inputs. This then leads to marketing (both strategy and execution) that’s technically compliant and commercially ineffective.
Forrester’s analysis of healthcare go-to-market struggles identifies the strategy phase as where medical device and diagnostics companies most commonly falter.
Even more specifically, waiting for regulatory approval before building a go-to-market plan, rather than developing both in parallel.
The commercial groundwork, audience definition, buyer persona mapping, and market sizing, is left until the product has cleared regulatory review, by which point the market window is already narrowing.
This, and the other challenges we will explore are not new. But they are consistently underestimated in ways that cost time, budget, and market position.
Regulatory Complexity That Shapes Everything, Not Just the Legal Review
Regulatory compliance in MedTech is not a sign-off step at the end of a creative process.
It is a constraint that shapes the brief, the claims, the evidence requirements, and the approval timeline before a single word of copy is written.
The frameworks vary significantly by market. FDA rules in the US, MDR and IVDR in Europe, PMDA in Japan, TGA in Australia. Each operates differently, and a campaign that clears one framework may require substantive rethinking for another.
Digital health and diagnostics companies add another layer: the regulatory classification of software as a medical device is still evolving across jurisdictions, creating genuine ambiguity about what constitutes a marketing claim versus a product description.
The practical consequence is that marketing teams without direct regulatory experience routinely underestimate how much time compliance review adds to content production. Timelines built without that understanding produce content that either misses the brief, or misses the market window while waiting for approval.
The answer isn’t to slow everything down. It’s to build compliance into the content process from the start rather than treating it as an obstacle at the end. That requires marketing teams and regulatory or legal teams working from the same brief rather than sequentially passing it along between departments.
A Fragmented Audience With No Single Decision-Maker
Medical device and digital health purchasing decisions involve multiple stakeholders who evaluate the same product through completely different lenses, on different timescales, and with different objections.
A clinical team evaluates usability, workflow integration, and clinical evidence.
A procurement team evaluates commercial terms, vendor stability, and total cost of ownership.
An IT or data team evaluates integration requirements, security standards, and data governance.
A health system leadership team evaluates strategic fit, reputational risk, and long-term value.
In some markets, an external health technology assessment body evaluates the economic case for reimbursement.
Marketing that tries to speak to all of these audiences simultaneously with a single set of materials ends up speaking clearly to none of them.
And yet that’s still the most common approach: one product brochure, one website page, one set of talking points trying to do every job at once.
Building distinct content and communication pathways for each stakeholder type is not a nice-to-have in MedTech. It’s the difference between marketing that moves a sale forward and marketing that sits in a content library nobody uses.
Data Privacy as a Marketing Constraint, Not Just a Legal One
Data privacy in healthcare isn’t just a compliance requirement. It directly limits what MedTech marketers can do with the channels and data tools that most other industries take for granted.
HIPAA in the US restricts how patient data can be handled across marketing operations. GDPR in Europe sets strict requirements for consent, data retention, and cross-border data transfer.
Add market-specific regulations in other geographies and the picture becomes complex quickly. The implication is that some of the standard digital marketing infrastructure, including the standard expected retargeting pixels, behavioral tracking, and third-party data enrichment requires careful legal review before deployment in a healthcare context, and in some cases require specific consent mechanisms and data processing agreements before they can be deployed legally.
This isn’t just a legal team problem.
It shapes which channels are viable, how audience data can be collected and used, and what measurement infrastructure is permissible.
MedTech marketers who don’t understand these constraints often discover them mid-campaign, at which point the cost of fixing the problem is significantly higher than building for it correctly at the start. Or they ignore them and put their business at risk of costly penalties later.
For a deeper look at how privacy regulation intersects with healthcare marketing specifically, the HIPAA compliance guide covers the marketing implications in practical terms.
Differentiating in a Market Where Everyone Claims the Same Things
The MedTech market has a differentiation problem.
Spend an hour reviewing the marketing output of competing device manufacturers or digital health platforms and a pattern emerges: the same claims, the same language, the same stock imagery, the same proof points positioned in the same order.
“Innovative.” “Patient-centric.” “Clinically proven.” “Trusted by healthcare professionals worldwide.”
These phrases appear so consistently across the category that they’ve stopped carrying any meaning at all.
The challenge is genuine. Clinical evidence is often the strongest differentiator available, but it’s owned by medical affairs rather than marketing, written in the language of study design rather than brand storytelling, and constrained by what regulatory frameworks permit you to claim from it.
By the time legal has reviewed the copy, the clinical differentiation that made the product distinctive has often been flattened into something that reads exactly like a competitor’s approved language.
Getting out of this trap requires doing the harder work of finding what is genuinely specific about the product experience, the implementation support, the outcome data, or the company’s particular depth in a clinical area, and communicating that specificity in a way that is defensible and distinct. That’s a harder and more expensive brief than most MedTech marketing teams are given.
It’s also the one that produces marketing worth paying attention to.
Keeping Pace With Technology That Moves Faster Than Marketing Can Plan For
MedTech is a fast-moving category.
We’re seeing an explosion of AI-assisted diagnostics, remote patient monitoring, digital therapeutics, and advanced surgical robotics. The product landscape is evolving faster than most marketing infrastructure is built to accommodate, even for those replacing their marketing strategy, team and execution with AI agents.
The challenge this creates for marketing, both in quality and effectiveness, is layered.
New product categories require new audience education before demand can be created. The clinical evidence base for emerging technologies is still being established, which limits the claims available to marketing. And the regulatory frameworks governing emerging MedTech categories are in active development, creating the same ambiguity on the compliance side that characterizes early-stage markets in any regulated industry.
For established MedTech companies expanding into digital health or adding software components to existing device portfolios, this creates a specific tension: the brand credibility built in the device market doesn’t automatically transfer to a software buyer, and the go-to-market logic that worked for hardware doesn’t work for a SaaS-model digital health platform.
The companies that manage this well treat the product evolution and the marketing strategy as connected decisions rather than sequential ones.
By the time a new product category is market-ready, the marketing foundation (the content, the audience understanding, the channel presence) should already exist.
Building it from scratch at launch is one of the most reliable ways to delay commercial traction in a market where the window is already narrow.
What These Challenges Have in Common
Every one of these challenges reflects the same underlying reality: MedTech marketing is structurally more complex than marketing in most other categories, and approaches that are built for less complex environments don’t transfer cleanly.
That’s not a reason for paralysis.
It’s a reason to be deliberate about strategy before channel selection, to build compliance into the brief rather than onto the end of it, and to treat audience complexity as an input to communication design rather than an obstacle to simplify away.
For a practical breakdown of which digital marketing channels and tactics actually hold up under these conditions, and how to structure them into a connected strategy, the guide to digital marketing for medical devices covers the execution side in detail.
And if you’re navigating international markets alongside these challenges, the global marketing guide for MedTech companies addresses what changes when you cross a border.
At LD, we work with MedTech companies at the point where marketing complexity outpaces internal capacity. If you want a direct view of where your current strategy has gaps, get in touch with our team.
